Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice

References

• El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–2636. doi: 10.1182/blood-2016-06-688432
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438. doi: 10.1182/blood-2015-11-679639
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–27. doi: 10.1016/S2352-3026(15)00289-6
   PubMed Web of Science ®Google Scholar
• Liu LW, Yn A, Gao F, et al. Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transplant Cell Ther. 2022;28(8):e510.1–e510.9. doi: 10.1016/j.jtct.2022.05.020
   Google Scholar
• Beauvais D, Drumez E, Blaise D, et al. Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study. Bone Marrow Transplant. 2021;56(6):1305–1315. doi: 10.1038/s41409-020-01178-6
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159–1164. doi: 10.1182/blood.V99.4.1159
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444. doi: 10.1056/NEJMoa1706640
   PubMed Web of Science ®Google Scholar
• Hakki M. Moving past ganciclovir and foscarnet: advances in CMV therapy. Curr Hematol Malig Rep. 2020;15(2):90–102. doi: 10.1007/s11899-020-00557-6
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines. Prevention and treatment of cancer-related infections (version 1.2023). Available from: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
   Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272. doi: 10.1016/S1473-3099(19)30107-0
   PubMed Web of Science ®Google Scholar
• Hakki M, Aitken SL, Danziger-Isakov L, et al. American society for transplant cell ther series: #3—prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(9):707–719. doi: 10.1016/j.jtct.2021.05.001
   PubMedGoogle Scholar
• Cesaro S, Ljungman P, Tridello G, et al. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT. Bone Marrow Transplant. 2023;58(2):203–208. doi: 10.1038/s41409-022-01863-8
   PubMed Web of Science ®Google Scholar
• Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33–42. doi: 10.1001/jama.2023.9106
   PubMed Web of Science ®Google Scholar
• Razonable RR. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. Curr Opin Infect Dis. 2018;31(4):286–291. doi: 10.1097/QCO.0000000000000459
   PubMed Web of Science ®Google Scholar
• Imlay HN, Kaul DR. Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients. Clin Infect Dis. 2021;73(1):156–160. doi: 10.1093/cid/ciaa1713
   PubMed Web of Science ®Google Scholar
• Saullo JL, Miller RA. Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients. Annu Rev Med. 2023;74(1):89–105. doi: 10.1146/annurev-med-042921-124739
   PubMedGoogle Scholar
• Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613. doi: 10.1128/AAC.01794-13
   PubMed Web of Science ®Google Scholar
• Perchetti GA, Biernacki MA, Xie H, et al. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis. Bone Marrow Transplant. 2023;58(4):430–436. doi: 10.1038/s41409-023-01920-w
   PubMed Web of Science ®Google Scholar
• Popping S, Dalm VASH, Lübke N, et al. Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with primary immunodeficiency. Open Forum Infect Dis. 2019;6(9):ofz375. doi: 10.1093/ofid/ofz375
   PubMed Web of Science ®Google Scholar
• Paolucci S, Campanini G, Cassaniti I, et al. Emergence of letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report. BMC Infect Dis. 2021;21:994. doi: 10.1186/s12879-021-06694-4
   PubMed Web of Science ®Google Scholar
• Jeng LB, Lee SG, Soin AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2018;18(6):1435–1446. doi: 10.1111/ajt.14623
   PubMed Web of Science ®Google Scholar
• Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016;213(1):23–30. doi: 10.1093/infdis/jiv352
   PubMed Web of Science ®Google Scholar
• Ljungman P, Schmitt M, Marty FM, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70(8):1525–1533. doi: 10.1093/cid/ciz490
   PubMed Web of Science ®Google Scholar
• Sassine J, Khawaja F, Shigle TL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era. Clin Infect Dis. 2021;73(8):1346–1354. doi: 10.1093/cid/ciab298
   PubMed Web of Science ®Google Scholar
• Su Y, Stern A, Karantoni E, et al. Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study. Clin Infect Dis. 2022;75(5):795–804. doi: 10.1093/cid/ciab1064
   PubMed Web of Science ®Google Scholar
• Derigs P, Radujkovic A, Schubert ML, et al. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Ann Hematol. 2021;100(8):2087–2093. doi: 10.1007/s00277-020-04362-2
   PubMed Web of Science ®Google Scholar
• Anderson A, Raja M, Vazquez N, et al. Clinical “real-world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020;34(7):e13866. doi: 10.1111/ctr.13866
   PubMed Web of Science ®Google Scholar
• Yoshimura H, Satake A, Ishii Y, et al. Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis. J Infect Chemother. 2022;28(9):1317–1323. doi: 10.1016/j.jiac.2022.05.019
   PubMed Web of Science ®Google Scholar
• Mori Y, Jinnouchi F, Takenaka K, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021;56(4):853–862. doi: 10.1038/s41409-020-01082-z
   PubMed Web of Science ®Google Scholar
• Takenaka K, Fuji S, Matsukawa T, et al. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection. Ann Hematol. 2024;103(1):285–296. doi: 10.1007/s00277-023-05474-1
   PubMedGoogle Scholar
• Wolfe D, Zhao Q, Siegel E, et al. Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease. Cancers (Basel). 2021;13(21):5572. doi: 10.3390/cancers13215572
   PubMed Web of Science ®Google Scholar
• Malagola M, Radici V, Farina M, et al. CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2024;59(1):138–140. doi: 10.1038/s41409-023-02124-y
   PubMed Web of Science ®Google Scholar
• Richert-Przygonska M, Jaremek K, Debski R, et al. Letermovir prophylaxis for cytomegalovirus infection in children after hematopoietic cell transplantation. Anticancer Res. 2022;42(7):3607–3612. doi: 10.21873/anticanres.15848
   PubMed Web of Science ®Google Scholar
• Styczyński J, Tridello G, Xhaard A, et al. Use of letermovir in off-label indications: infectious diseases working party of European society of blood and marrow transplantation retrospective study. Bone Marrow Transplant. 2021;56(5):1171–1179. doi: 10.1038/s41409-020-01166-w
   PubMed Web of Science ®Google Scholar
• Körholz KF, Füller MA, Hennies M, et al. Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients. Paediatr Drugs. 2023;25(2):225–232. doi: 10.1007/s40272-022-00547-6
   PubMed Web of Science ®Google Scholar
• César T, Le MP, Klifa R, et al. Letermovir for CMV prophylaxis in very high-risk pediatric hematopoietic stem cell transplantation recipients for inborn errors of immunity. J Clin Immunol. 2023;44(1):6. doi: 10.1007/s10875-023-01617-1
   PubMed Web of Science ®Google Scholar
• Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biol Blood Marrow Transplant. 2020;26(5):978–984. doi: 10.1016/j.bbmt.2020.01.027
   PubMed Web of Science ®Google Scholar
• Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;21(6):e13187. doi: 10.1111/tid.13187
   PubMed Web of Science ®Google Scholar
• Menzel K, Kothare P, McCrea JB, et al. Absorption, metabolism, distribution, and excretion of letermovir. Curr Drug Metab. 2021;22(10):784–794. doi: 10.2174/18755453MTE05NDYa1
   PubMed Web of Science ®Google Scholar
• FDA label prevymis ® (letermovir). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209939s012,209940s011lbl.pdf
   Google Scholar
• McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharmacol. 2019;59(10):1331–1339. doi: 10.1002/jcph.1423
   PubMed Web of Science ®Google Scholar
• Kropeit D, von Richter O, Stobernack HP, et al. Pharmacokinetics and safety of letermovir coadministered with cyclosporine a or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(1):9–21. doi: 10.1002/cpdd.388
   PubMed Web of Science ®Google Scholar
• Adedoyin A, Fancourt C, Menzel K, et al. Assessment of pharmacokinetic interaction between letermovir and fluconazole in healthy participants. Clin Pharmacol Drug Dev. 2021;10(2):198–206. doi: 10.1002/cpdd.852
   PubMed Web of Science ®Google Scholar
• Marshall WL, McCrea JB, Macha S, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58(7):897–904. doi: 10.1002/jcph.1094
   PubMed Web of Science ®Google Scholar
• Nakashima T, Inamoto Y, Fukushi Y, et al. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;113(6):872–876. doi: 10.1007/s12185-021-03105-x
   PubMed Web of Science ®Google Scholar
• McCrea JB, Menzel K, Fancourt C, et al. Evaluation of the inhibitory effects of itraconazole on letermovir. Br J Clin Pharmacol. 2023;89(7):2122–2130. doi: 10.1111/bcp.15677
   PubMed Web of Science ®Google Scholar
• Hill JA, Zamora D, Xie H, et al. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. Blood Adv. 2021;5(16):3113–3119. doi: 10.1182/bloodadvances.2021004362
   PubMed Web of Science ®Google Scholar
• Mori Y, Harada T, Yoshimoto G, et al. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis. Int J Hematol. 2022;116(2):258–265. doi: 10.1007/s12185-022-03348-2
   PubMed Web of Science ®Google Scholar
• Nho D, Lee R, Cho SY, et al. Cytomegalovirus infection after allogeneic hematopoietic cell transplantation under 100-day letermovir prophylaxis: a real-world 1-year follow-up study. Viruses. 2023;15(9):1884. doi: 10.3390/v15091884
   PubMed Web of Science ®Google Scholar
• Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2023;S2352-3026(23):00344–7.
   Google Scholar
• Politikos I, Lau C, Devlin SM, et al. Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. Blood Adv. 2022;6(24):6291–6300. doi: 10.1182/bloodadvances.2022008047
   PubMed Web of Science ®Google Scholar
• Sourisseau M, Faure E, Béhal H, et al. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. Blood Adv. 2023;7(5):856–865. doi: 10.1182/bloodadvances.2022008667
   PubMed Web of Science ®Google Scholar
• Callens R, Colman S, Delie A, et al. Immunologic monitoring after allogeneic stem cell transplantation: T-SPOT.CMV and QuantiFERON-CMV, are they the same? Transplant Cell Ther. 2023;29(6):392.e1–392. doi: 10.1016/j.jtct.2023.03.018
   PubMedGoogle Scholar
• Reusing JO Jr, Agena F, Kotton CN, et al. QuantiFERON-CMV as a predictor of CMV events during preemptive therapy in CMV-seropositive kidney transplant recipients. Transplantation. 2023. doi: 10.1097/TP.0000000000004870
   PubMedGoogle Scholar
• Santos Bravo M, Tilloy V, Plault N, et al. Assessment of UL56 mutations before letermovir therapy in refractory cytomegalovirus transplant recipients. Microbiol Spectr. 2022;10(2):e0019122. doi: 10.1128/spectrum.00191-22
   PubMed Web of Science ®Google Scholar
• Cassaniti I, Colombo AA, Bernasconi P, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21(4):1622–1628. doi: 10.1111/ajt.16450
   PubMed Web of Science ®Google Scholar
• Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138(1):34–43. doi: 10.1182/blood.2020009396
   PubMed Web of Science ®Google Scholar
• Gabanti E, Borsani O, Colombo AA, et al. Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis. Transplant Cell Ther. 2022;28(4):e211.1–e211.9. doi: 10.1016/j.jtct.2022.01.008
   Google Scholar
• Fuji S, Einsele H, Kapp M. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Curr Opin Infect Dis. 2017;30(4):372–376. doi: 10.1097/QCO.0000000000000375
   PubMed Web of Science ®Google Scholar
• Jiang Z, Fan Z, Zhang T, et al. Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024. doi: 10.1111/bjh.19282
   PubMedGoogle Scholar
• Huntley D, Talaya A, Giménez E, et al. Features of cytomegalovirus DNAemia blips in allogeneic hematopoietic stem cell transplant recipients: Implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transplant. 2020;26(5):972–977. doi: 10.1016/j.bbmt.2020.01.015
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703–1711. doi: 10.1111/ajt.15764
   PubMed Web of Science ®Google Scholar
• Linder KA, Kovacs C, Mullane KM, et al. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transpl Infect Dis. 2021;23(4):e13687. doi: 10.1111/tid.13687
   PubMedGoogle Scholar